Sanofi-a Ventis Deutschland Gmbh

Bernward Schoelkens

Detlef Kozian

Sylvain Ricard

Sandrine Mace

Jean-Francois Deleuze

Karl-Ernst Siegler

Hertzel Gerstein

Stefan Schaefer

Norbert Bender

Badrudin Rangoonwala

Anders Ljunggren

Hetzel Gerstein

Gilles Dagenais

The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.

Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism

The present invention is directed to a method identifying a risk for a thrombogenic disorder, to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.

Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-lle347 polymorphism

Growing community of inventors

Kelkheim, Germany

Bernward Schoelkens